{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:26Z","timestamp":1792801106639,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04648-4","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:13:35Z","timestamp":1769498015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unexpected pregnancy in a patient with AQP4-IgG\u2009+\u2009NMOSD after treatment with inebilizumab: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Feiyan","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"9\u201310","key":"4648_CR1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.18071\/isz.74.0309","volume":"74","author":"Z Illes","year":"2021","unstructured":"Illes Z. [Treatment and new evidences in neuromyelitis optica spectrum disorder]. Ideggyogy Sz. 2021;74(9\u201310):309\u201321.","journal-title":"Ideggyogy Sz"},{"key":"4648_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800666","volume":"12","author":"S Deng","year":"2021","unstructured":"Deng S, Lei Q, Lu W. Pregnancy-related attack in neuromyelitis optica spectrum disorder with AQP4-IgG: a single-center study and meta-analysis. Front Immunol. 2021;12:800666.","journal-title":"Front Immunol"},{"issue":"1","key":"4648_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","volume":"86","author":"MM Nour","year":"2016","unstructured":"Nour MM, et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis Optica spectrum disorder. Neurology. 2016;86(1):79\u201387.","journal-title":"Neurology"},{"issue":"10206","key":"4648_CR4","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"B Cree","year":"2019","unstructured":"Cree B, et al. Inebilizumab for the treatment of neuromyelitis Optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"key":"4648_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5120107","author":"D Chen","year":"2016","unstructured":"Chen D, et al. Inebilizumab, a b cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016. https:\/\/doi.org\/10.3390\/jcm5120107.","journal-title":"J Clin Med"},{"issue":"1","key":"4648_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-022-00421-0","volume":"12","author":"P Iyer","year":"2023","unstructured":"Iyer P, Dobson R. Multiple sclerosis in pregnancy: a commentary on disease modification and symptomatic drug therapies. Neurol Ther. 2023;12(1):1\u201310.","journal-title":"Neurol Ther"},{"issue":"10","key":"4648_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/jamaneurol.2025.2559","volume":"82","author":"KM Krysko","year":"2025","unstructured":"Krysko KM. Emergence of anti-CD20 therapies for individuals with multiple sclerosis planning pregnancy. JAMA Neurol. 2025;82(10):983\u20134.","journal-title":"JAMA Neurol"},{"issue":"1","key":"4648_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/pn-2022-003426","volume":"23","author":"R Dobson","year":"2023","unstructured":"Dobson R, et al. Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. Pract Neurol. 2023;23(1):6\u201314.","journal-title":"Pract Neurol"},{"issue":"4","key":"4648_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","volume":"22","author":"KM Krysko","year":"2023","unstructured":"Krysko KM, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22(4):350\u201366.","journal-title":"Lancet Neurol"},{"issue":"10","key":"4648_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaneurol.2025.2550","volume":"82","author":"A Gavoille","year":"2025","unstructured":"Gavoille A, et al. Therapeutic management during pregnancy and relapse risk in women with multiple sclerosis. JAMA Neurol. 2025;82(10):994\u20131003.","journal-title":"JAMA Neurol"},{"issue":"3","key":"4648_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40262-021-01071-5","volume":"61","author":"L Yan","year":"2022","unstructured":"Yan L, et al. Population Pharmacokinetic modeling of inebilizumab in subjects with neuromyelitis Optica spectrum Disorders, systemic sclerosis, or relapsing multiple sclerosis. Clin Pharmacokinet. 2022;61(3):387\u2013400.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"4648_CR12","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1007\/s00415-020-10235-5","volume":"268","author":"T Holmoy","year":"2021","unstructured":"Holmoy T, et al. Recent progress in maintenance treatment of neuromyelitis Optica spectrum disorder. J Neurol. 2021;268(12):4522\u201336.","journal-title":"J Neurol"},{"issue":"3","key":"4648_CR13","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","volume":"5","author":"G Das","year":"2018","unstructured":"Das G, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4648_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000734","author":"JB Smith","year":"2020","unstructured":"Smith JB, et al. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020. https:\/\/doi.org\/10.1212\/NXI.0000000000000734.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4648_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101137","volume":"48","author":"N Bast","year":"2025","unstructured":"Bast N, et al. Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry. The Lancet Regional Health. 2025;48:101137.","journal-title":"The Lancet Regional Health"},{"key":"4648_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ph16050770","author":"P Gklinos","year":"2023","unstructured":"Gklinos P, Dobson R. Monoclonal antibodies in pregnancy and breastfeeding in patients with multiple sclerosis: a review and an updated clinical guide. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16050770.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4648_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124","author":"F Paul","year":"2023","unstructured":"Paul F, et al. International delphi consensus on the management of AQP4-IgG\u2009+\u2009NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/NXI.0000000000200124.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"4648_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5603\/pjnns.100945","volume":"59","author":"B Zakrzewska-Pniewska","year":"2025","unstructured":"Zakrzewska-Pniewska B, et al. Update on diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - recommendations of section of multiple sclerosis and neuroimmunology of Polish Neurological Society. Neurol Neurochir Pol. 2025;59(1):6\u201319.","journal-title":"Neurol Neurochir Pol"},{"issue":"8","key":"4648_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/1352458509106512","volume":"15","author":"HL Pellkofer","year":"2009","unstructured":"Pellkofer HL, et al. Course of neuromyelitis Optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler. 2009;15(8):1006\u20138.","journal-title":"Mult Scler"},{"issue":"2","key":"4648_CR20","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1212\/NXI.0000000000000542","volume":"6","author":"J Miranda-Acuna","year":"2019","unstructured":"Miranda-Acuna J, et al. Rituximab during pregnancy in neuromyelitis optica: A case report. Neurol Neuroimmunol Neuroinflamm. 2019;6(2):e542.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"4648_CR21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/ene.14274","volume":"27","author":"SH Kim","year":"2020","unstructured":"Kim SH, et al. Outcome of pregnancies after onset of the neuromyelitis Optica spectrum disorder. Eur J Neurol. 2020;27(8):1546\u201355.","journal-title":"Eur J Neurol"},{"issue":"1","key":"4648_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T Kumpfel","year":"2024","unstructured":"Kumpfel T, et al. Update on the diagnosis and treatment of neuromyelitis Optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis Optica study group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"issue":"1","key":"4648_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/13524585221130934","volume":"29","author":"S Vukusic","year":"2023","unstructured":"Vukusic S, et al. Pregnancy and neuromyelitis Optica spectrum disorders: 2022 recommendations from the French multiple sclerosis society. Mult Scler. 2023;29(1):37\u201351.","journal-title":"Mult Scler"},{"issue":"3","key":"4648_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","volume":"16","author":"Y Mao-Draayer","year":"2020","unstructured":"Mao-Draayer Y, et al. Neuromyelitis Optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020;16(3):154\u201370.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"4648_CR25","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458514525870","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis Optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20(11):1533\u201340.","journal-title":"Mult Scler"},{"key":"4648_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000913","author":"T Kumpfel","year":"2021","unstructured":"Kumpfel T, et al. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany. Neurol Neuroimmunol Neuroinflamm. 2021. https:\/\/doi.org\/10.1212\/NXI.0000000000000913.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"4648_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","volume":"23","author":"B Cree","year":"2024","unstructured":"Cree B, et al. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol. 2024;23(6):588\u2013602.","journal-title":"Lancet Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04648-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:15:18Z","timestamp":1771420518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04648-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4648"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04648-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7313873\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki Ethical Principles and was approved by the ethics committee of the Third Affiliated Hospital of Sun Yat-sen University (CR2025-014-01). Written informed consent for study participation was obtained appropriately for the two participants (one adult patient, one infant): the adult provided consent directly, while the infant\u2019 s consent was obtained from their parents (legal guardians).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of de-identified data and images in this report was obtained in accordance with ethical standards: the adult patient provided direct written informed consent, and the infant\u2019s parents (legal guardians) provided written informed consent on the infant\u2019s behalf (as the infant is aged\u2009<\u200916 years).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}